In This Section

Program: Tuesday, July 21

Wednesday, July 22 Thursday, July 23 Friday, July 24

Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Tuesday, July 21

Tuesday, July 21

REGISTRATION

12-9 p.m. | Grand Ballroom Prefunction

Educational Session 1: Global Drug Discovery and Development: Progress, Challenges, and the Path Forward

2:30-3:30 p.m. | Constitution Ballroom A

Session Chair: Geetika Srivastava, U.S. Food and Drug Administration, Silver Spring, Maryland

  • 2 p.m. | Introduction
  • 2:10 p.m. | Seock-Ah Im, Seoul National University, Seoul, Korea
  • 2:20 p.m. | Anthony Joshua, Garvan Institute of Medical Research, Sydney, NSW, Australia
  • 2:30 p.m. | Takafumi Koyama, National Cancer Center Japan, Tokyo, Japan
  • 2:40 p.m. | Pei Jye Voon, Sarawak General Hospital, Sarawak, Malaysia
  • 2:50 p.m. | Li Yan, US Chinese Anti-Cancer Association, Martinez, California
  • 3 p.m. | Panel Discussion

Educational Session 2: Case Studies in Drug Discovery and Development

3:30-5:30 p.m. | Constitution Ballroom B

Session Chair: Norbert Kraut, Boehringer Ingelheim, Vienna, Austria

  • 3:30 p.m. | Introduction
  • 3:40 p.m. | Zongertinib (irreversible HER2 TKI for HER2mut+ nsqNSCLC)
    Preclinical     – Ralph A. Neumüller, Boehringer Ingelheim, Vienna, Austria
    Clinical – John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 4:15 p.m. | Ziftomenib (menin inhibitor for NPM1-mutated AML)
    Preclinical     – Francis Burrows, Kura Oncology, San Diego, California
    Clinical – Eunice S. Wang, Roswell Park Comprehensive Cancer Center, Roswell Park, New York
  • 4:50 p.m. | Datopotamab Deruxtecan (Dato-DXd) (TROP2-targeted ADC for the treatment of hormone receptor-positive, HER2-negative breast cancer)
    Preclinical     – Daisuke Okajima, Daiichi-Sankyo, Tokyo, Japan
    Clinical – Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

Break

5:30-6 pm | Grand Ballroom Prefunction

Welcome and Opening Session

6-8 p.m. | Grand Ballroom

  • 6 p.m. | Welcome and Introductory Remarks
    Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
  • 6:10 p.m. | Introduction
    Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
  • 6:15 p.m. | Alexis Borisy, Curie.Bio, Boston, Massachusetts
  • 6:30 p.m. | Introduction
    Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 6:35 p.m. | Chris Boshoff, Pfizer, New York, New York
  • 6:50 p.m. | Introduction
    Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
  • 6:55 p.m. | David Schenkein, Google Ventures, Mountain View, California
  • 7:10 p.m. | Panel Discussion

Opening Reception

8:15-10 p.m. | Back Bay Ballroom